{
    "clinical_study": {
        "@rank": "94037", 
        "arm_group": [
            {
                "arm_group_label": "Exendin 9,39", 
                "arm_group_type": "Experimental", 
                "description": "Subjects randomized to this arm will receive an infusion of exendin 9,39 of 300mmol/kg/min for 360 minutes."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subjects randomized to this arm will receive a saline infusion for 360 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "The study is being undertaken to understand how a gastric bypass can affect a subject's\n      diabetes even prior to their losing significant amounts of weight. The hypothesis of this\n      study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration\n      in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery."
        }, 
        "brief_title": "The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of >\n             110 mg/dL\n\n          -  Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).\n\n        Exclusion Criteria:\n\n          -  Subjects taking thiazolidinediones\n\n          -  Subjects with active systemic illness\n\n          -  Subjects with active microvascular or macrovascular complications of their diabetes\n\n          -  For female subject: positive pregnancy test at the time of enrollment in study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01843855", 
            "org_study_id": "11-000161", 
            "secondary_id": [
                "R01DK082396", 
                "UL1RR024150"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Exendin 9,39", 
                "description": "Exendin 9,39 is a competitive antagonist of endogenous GLP-1.", 
                "intervention_name": "Exendin 9,39", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "A saline infusion will be given to match the study drug infusion.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gastric Inhibitory Polypeptide", 
                "Incretins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Gastric Bypass", 
            "bariatric surgery", 
            "glucose metabolism"
        ], 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905-0001"
                }, 
                "name": "Mayo Clinic"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Adrian Vella, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The total disposition index equals the product of insulin secretion and insulin sensitivity.", 
            "measure": "Change in Total Disposition Index from Study 1 (pre-RYGB) to Study 2 (post-RYGB)", 
            "safety_issue": "No", 
            "time_frame": "baseline, 4 weeks post-operative intervention"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01843855"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Adrian Vella", 
            "investigator_title": "Consultant, Endocrinology", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "National Center for Research Resources (NCRR)", 
                    "agency_class": "NIH"
                }
            ], 
            "lead_sponsor": {
                "agency": "Adrian Vella", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}